For information on this past event please contact Meetings Management

Wednesday 9th April 2008

SESSION 1:
OPENING PLENARY SESSION
Chair: Uli Fruth (WHO, Geneva, Switzerland)

Welcome & Opening Remarks

09.30-10.00
Opening Plenary:
‘Development of new vaccines to address the TB pandemic’
Jerald C. Sadoff (Aeras Global TB Vaccine Foundation, Rockville, Maryland, USA)

10.00-10.30
‘Rational vaccine design – dreams, genes and reality’
Carmen Giefing (Intercell AG, Vienna, Austria)

10.30-11.00
‘A regulatory perspective on product, clinical and global challenges to TB vaccine development’
Michael J. Brennan (CBER, FDA, Rockville, Maryland, USA)

11.00-11.30
Coffee Break and Poster Set-Up

SESSION 2:
TB VACCINE INITIATIVE UPDATES
Moderator: Uli Fruth (WHO, Geneva, Switzerland)

Global programmes facilitating TB vaccine development:

Stop TB Partnership Working Group on New TB Vaccines:
Recent Developments & Update

11.30-11.40
Overview on Stop TB Working Group on New Vaccines
Michel Greco (Parteurop, Lyon, France)

11.40-11.50
New Approaches to TB Vaccine R&D Task Force
Jerry Sadoff (Aeras Global TB Vaccine Foundation, Rockville, Maryland, USA)

11.50-12.10
Laboratory Assays Harmonization Task Force
Uli Fruth (WHO, Switzerland) and Jelle Thole (TBVI, The Netherlands)

12.10-12.20
Clinical Trials of new TB vaccines Task Force
Hassan Mahomed (University of Cape Town, South Africa)

12.20-12.30
Economics and Product Profiles Task Force
Lew Barker (Aeras Global TB Vaccine Foundation, Rockville, Maryland, USA)

12.30-12.40
Advocacy, Communication and Social Mobilization Task Force
Lydia Mungherera (TASO, Kampala, Uganda)

12.40-13.10
Discussion Time: Input from TB vaccine community
Discussion Leader: Uli Fruth (WHO, Switzerland)

13.10-14.10
Lunch & Posters

SESSION 2:
CONTINUED
Moderator: Alex von Gabain (Intercell AG, Vienna, Austria)

Presentations from:

14.10-14.30
TBVAC Update
Jelle Thole (TBVI, The Netherlands)

14.30-14.50
Aeras Global TB Vaccine Foundation
Donata R. Sizemore (Aeras Global TB Vaccine Foundation, USA)

14.50-15.10
US National Institutes of Health Update
Karen A. Lacourciere (NIH/NIAID, USA)

15.10-15.30
Bill & Melinda Gates Foundation
Jan Gheuens

15.30-16.00
Tea Break & Posters

SESSION 3:
BIOMARKERS, IMMUNE CORRELATES & SURVEILLANCE
Moderator: Michael J. Brennan (CBER/FDA, USA)

16.00-16.30
‘Biomarkers in TB as prerequisite for TB vaccine research’
Shreemanta Parida and Stefan Kaufmann (Max-Planck-Institute for Infection Biology, Berlin, Germany)

16.30-17.00
‘BCG-induced immune correlates of protection against infant tuberculosis’
Willem Hanekom et al. (University of Cape Town, South Africa)

17.00-17.20
‘Impact of surveillance methodology on measured incidence of pulmonary tuberculosis in children less than 2 years of age – interim findings’
Mark Hatherill et al. (University of Cape Town, South Africa)

Evening:
18.45-19.45
TBV 2008 Welcome Reception at the Centenial Ballroom A&B Marriott Century Center Hotel